Andy Plump, Takeda R&D chief (Jeff Rumans for Endpoints News)

In its largest sin­gle-as­set pur­chase ever, Take­da snaps up TYK2 drug for $4B up­front

Take­da is buy­ing Nim­bus’ late-stage TYK2 in­hibitor, an oral drug for au­toim­mune dis­eases, for $4 bil­lion in cash up­front. That sets Take­da up to com­pete with Bris­tol My­ers Squibb, which got the first TYK2 in­hibitor ap­proval in Sep­tem­ber for pso­ri­a­sis.

The Nim­bus/Take­da deal is among the in­dus­try’s largest sin­gle-as­set pur­chas­es dat­ing back to 2008, af­ter Am­gen bought Ote­zla from Cel­gene in 2019 ($13.4 bil­lion to­tal), ac­cord­ing to Chris Doko­ma­ji­lar at Deal­For­ma. Nim­bus can get an­oth­er po­ten­tial $2 bil­lion if the drug, once on the mar­ket, reach­es sales mile­stones — $1 bil­lion for reach­ing an­nu­al net sales of $4 bil­lion and an­oth­er bil­lion for net sales of $5 bil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.